Is the Bitcoin Beast Awakening?

Is the Bitcoin Beast Awakening?

After languishing in a bear market that began when BTC hit $20,000 on December 17, 2017, Bitcoin has recently shown some life. On April 2nd the price rose 20% on high volume. The scuttlebut is a whale bought most of it, but either way the entire crypto market rose with its leader. Read More »

 

Super 7 Update – SPCK and DSNY

1) Superclick Reports Record Revenue and Net Income for the Fiscal Year Ended October 31, 2009 (1/13/09)

2) Destiny Media Q1 Record Revenues Jump 89% (1/14/09)

Pennyheaven Super 7 (2010)

Once again, our main criterion is growth: earnings, sales, and/or revenues must be increasing. The second criterion is profitability. All companies listed are currently profitable. Prices reflect close of business 12/31/09. Best of Luck!

1) Brekford Corp  BFDI (.15)
57,815,513 shares outstanding (s/o) as of 11/2/09
$1.06m cash; 86k debt
9-month sales up 16%
9-month net earnings (+ .01) v (- .03)
Market Cap – $8.67m

Brekford Corp. is a leading homeland technology service provider of fully integrated vehicle installation and rugged technology solutions geared towards mission critical operations. For more than a decade, the company has provided services to branches of the U.S. military, various federal entities and numerous security and public safety agencies. Brekford provides these agencies with an end-to-end suite of mobile products and services designed to streamline procurement and operations.

Brekford 360 Degree vehicle solutions provides complete vehicle upfitting, mobile data and video solutions including municipal financing and leasing services for agencies. The 360 Degree vehicle solutions approach provides customers with a one stop upfitting, cutting edge technology and installation service.

For more Company information, please see website: http://www.brekford.com

2) Biostar Pharmaceuticals, Inc.  BSPM (4.45)
23,240,899 s/o as of 11/10/09
$2.45m cash; 0 debt
9-month net sales up 52%
9-month net earnings (+ .37) v (+ .18)
Market Cap – $103.43m

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company’s most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for two patents.

3) Destiny Media Technologies  DSNY (.49)
52,059,647 s/o as of 11/26/09
$253k cash, 68k debt
Net income 2009 (+ .01) v (- .05) (2008)
Market Cap – $27.59m

From 10-K (11/30/2009)
Revenue continued to grow during our fourth quarter and was the highest in the Company’s history. Fourth quarter revenue was 77% higher than the same quarter in the prior year and more than 31% above the previous quarter in fiscal 2009. Total revenue for the quarter is $872,569 (third quarter fiscal 2009 – $665,829). Total revenue for the year was $2,560,447 (2008 – $1,578,888), an increase of approximately 62% over the fiscal 2008 year.

Destiny Media (http://www.dsny.com) is the developer of the Play MPE® system (http://www.plaympe.com) which the recording industry uses to securely distribute new pre-release music through the internet to trusted recipients such as radio, media and VIP’s. Real time usage statistics are available at http://www.plaympe.com/v4/company/plaympestats.php

4) Stellar Pharmaceuticals Inc  SLXCF (.98)
23,495,040 s/o as of 9/30/09
$1.91m cash; minimal debt
9-month net revenues up 61%
9-month net earnings (+ .01) v. (- .01)
Market Cap – $23.03m

Stellar Pharmaceuticals Inc has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc, for the treatment of osteoarthritis; and Uracyst, its patented technology for treatment of interstitial cystitis/painful bladder syndrome, an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22 BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

5) Superclick, Inc SPCK (.115)
45,312,251 s/o as of 8/31/09
$1.9m cash; 52k debt
9-month net revenue up 16%
9-month net (+ . 02) v. (+ .01)
Record quarterly revenues for the third quarter ending July 31, 2009
Market Cap – $5.21m

Superclick, Inc. through its wholly owned, Montreal-based subsidiary Superclick Networks, Inc., develops, manufactures, markets and supports the Superclick Internet Management System (SIMS(TM)), Monitoring and Management Application (MAMA(TM)) and Media Distribution System (MDS(TM)) in worldwide hospitality, conference center and event, multi-tenant unit (MTU) and university markets. Current clients include MTU residences and Candlewood Suites, Crowne Plaza, Fairmont Hotels and Resorts, Four Seasons Hotels and Resorts, Four Points by Sheraton, InterContinental Hotels Group PLC, Hilton, Holiday Inn, Holiday Inn Express, Hampton Inn, Mandarin Oriental Hotel Group Marriott, Novotel, Radisson, Sheraton, Westin and Wyndham hotels in Canada, the Caribbean and the United States.
Website: http://www.superclick.com/

6) Technical Communications TCCO (4.10)
1.47m s/o
5.42m cash; 0 debt
Market Cap – $6.02m

For the year ended September 26, 2009, the Company reported revenue of $7,752,000 and net income of $943,000, or $0.65 per share, as compared to revenue of $6,852,000 and net income of $1,061,000, or $0.75 per share, for fiscal 2008. For the quarter ended September 26, 2009, the Company reported net income of $235,000, or $0.16 per share, on revenue of $1,765,000, as compared to a net loss of $(87,000), or $(0.06) per share, on revenue of $1,204,000 for the quarter ended September 27, 2008.

TCC designs, manufactures, and supports superior grade secure communications systems that protect highly sensitive information transmitted over a wide range of data, voice and fax networks. TCC’s security solutions protect information privacy on every continent in over 110 countries. Government agencies, militaries, financial institutions, telecommunications carriers and multinational corporations worldwide rely on TCC to protect their communications networks.

Web Site: http://www.tccsecure.com

7) Tikcro Technologies TIKRF (.92)
~ 8.42m s/o
$7.4m cash; 0 debt
Market Cap – $7.75m

Tikcro Technologies Reports 2009 Third Quarter Results

Net income for the third quarter was $590,000 or $0.07 per diluted share. Net income for the nine months ended September 30, 2009 was $4.7 million or $0.56 per diluted share. Results for the third quarter included financial income of $692,000 primarily from to the valuation of Tikcro’s holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Tikcro holds 36% of BioCancell, taking into account the conversion of a convertible note and exercise of warrants, and 27% on a fully diluted basis. Shares of BioCancell are traded on the Tel Aviv Stock Exchange.

Tikcro Technologies has holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. BioCancell is conducting the following clinical trials in Israel and in the U.S. using its leading drug, BC-819:  – Phase IIb clinical trial for the treatment of superficial bladder carcinoma   cancer – Phase I/IIa clinical trial for the treatment of ovarian cancer – Phase I/IIa clinical trial for the treatment of pancreatic cancer.

DISCLAIMER, PLEASE READ
Please be advised that nothing within this notice shall constitute a solicitation or an offer to buy or sell any security mentioned herein. All statements made are our express opinion only and should be treated as such. Nothing within this notice should be considered personalized investment advice. Pennyheaven.com is neither a registered investment advisor nor affiliated with any broker or dealer. Any investments in stocks recommended in this notice should be made only after consulting with your investment advisor and only after reviewing the financial statements of the company. We reserve the right to trade in and out of these stocks at will, before, during, and/or after publication. We have not been compensated by any individual or company and we do not accept any paid promotion. Please do your own DD and trade only what is right for you.

Three Things to Like About Technical Communications

From SeekingAlpha.com

I am reluctant to write about Technical Communications Corp. (TCCO.OB), a microcap manufacturer of encrypted communications devices. It took me weeks to even accumulate a small position at the prices I wanted to pay. The stock is damn difficult to buy, at least near the bid.

But it’s worth it. There are three reasons why I think that Technical Communications Corp. is a stock worth owning:

1. Low float could make any move explosive. The float is only 1.35 million shares, and the total share count only 1.45 million. Another plus: unlike many microcaps, this one won’t dilute you into oblivion. The share count barely nudged over the past year.

2. Very low enterprise value-to-sales ratio. TCCO has a market cap of 6.23M and posted sales last year of over 7M. But TCCO.OB also has 3.97M, or $2.73/share, in cash and equivalents. Back that out and the EV/S ratio is only 0.33 (all figures courtesy of Yahoo Finance).

3. Technical Communications made $0.19/share last quarter ($0.17 fully diluted). Even without backing out the cash, that annualizes out to a forward P/E under 7. Back out the cash and the forward P/E drops under 4. Now I’m not sure that TCCO can earn as much over the next 3 quarters as it did the last quarter, but it seems to me there is what Seth Klarman might call a Margin of Safety here.

A few caveats. As mentioned, the stock is very thinly traded. Sales are concentrated — 2 customers account for 78% of revenues. One of the big customers is Uncle Sam. Also, the earnings were boosted in part because tax loss carryforwards allowed the company to dramatically cut its tax liability and avoid paying taxes. There are still over $3 million in carryforwards, so I don’t anticipate a big jump in the tax burden this year. However, if TCCO remains profitable, understand that at some point the carryforwards will be utilized and TCCO will have to pay taxes just like you and me.

(TCCO closed today at $4.04)

Artificial Life, Inc. Announces Equity Investment from 3M and Strategic Alliance Agreement

Oct 26 – Artificial Life, Inc., (OTC Bulletin Board: ALIF) and 3M Company (“3M”; NYSE: MMM) today announced the signing of a securities purchase agreement (the “Purchase Agreement”) and a strategic alliance agreement between Artificial Life, Inc. and 3M Company.

Under the Purchase Agreement, Artificial Life, Inc. sold to 3M 6,447,491 shares of its common stock at a price of $1.00 per share, for an aggregate consideration of $6,447,491. The basic and diluted number of shares outstanding immediately after the transaction is 56,984,858 and 64,474,911, respectively. The proceeds will fund an equity contribution by 3M, representing a 10% equity interest in Artificial Life, calculated on a fully diluted basis.

Besides the investment, 3M and Artificial Life have entered into an alliance agreement (the “Alliance Agreement”) outlining the parties intent to collaborate in the coming years in projects related to the research and development of new mobile device products and technology. In addition, the Alliance Agreement provides that 3M and Artificial Life plan to cooperate in connection with the marketing of certain of Artificial Life’s existing and new products. The focus of the cooperation under the Alliance Agreement is expected to be in the following areas:

— General mobile and broadband applications and technologies
— Digital Watermarking
— Virtual Reconstruction of 2D and 3D Objects
— Augmented Reality
— 3D Image processing
— Object recognition
— Mobile Healthcare and Diabetes Solutions
— Mobile Marketing and M-Commerce Platform

“We are excited to become an investor in Artificial Life,” said Stefan Gabriel, president, 3M New Ventures. “We are looking forward to collaborating with Artificial Life on a number of exciting technology applications in these fast growing markets all across the wide range of 3M businesses.”

“We are honored that 3M has chosen us for a strategic investment and as a new cooperation partner in the mobile space. The investment and the alliance agreement with 3M provide a strong, global business opportunity for us. The cooperation will allow us to create innovative business and lifestyle applications for one of the leading innovators in the business world and the general public. We are looking forward to working with 3M on many projects in the coming years,” said Eberhard Schoneburg, CEO of Artificial Life, Inc.

The issuance of the shares of Artificial Life’s common stock in connection with the Purchase Agreement has not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy Artificial Life’s common stock.

Super 7 Mid-Year Update

The Pennyheaven Super 7 (2009) had an exceptional first half thanks largly to ZAGG which closed June 30th up a whopping 639% for the year. As an index the Super 7 gained 114% with 4 out of the 7 in the black.

super7-063009